Johnson & Johnson (JNJ) has discontinued a Phase 2 study of its drug TAR-200 for the treatment of muscle-invasive bladder ...

Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of ...

Researchers are a step closer to revolutionizing how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

Johnson & Johnson has discontinued its SunRISe-2 study for TAR-200 in bladder cancer patients not undergoing radical ...

J&J acquired rights to the silicone-based drug delivery service used in TAR-200, which allows for the continuous release of ...

Pharma stock Theralase Technologies (TSXV:TLT) announced a significant update on its ongoing bladder cancer clinical study ...

The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an ...

A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) has identified a promising drug ...

Researchers are a step closer to revolutionising how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

Cathy Lee Mendelsohn, PhD A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) has ...

A groundbreaking protocol promises significant advances for patients with bladder cancer. New therapeutic combinations show ...

The 2024 American Society for Radiation Oncology (ASTRO) annual meeting held in Washington D.C., between September 29 and ...